Palliative treatment of germ cell cancer

Christoph Oing; Patrizia Giannatempo; Friedemann Honecker; Karin Oechsle; Carsten Bokemeyer; Jörg Beyer

doi:10.1016/j.ctrv.2018.10.007

Palliative treatment of germ cell cancer

Cancer Treat Rev. 2018 Dec:71:102-107. doi: 10.1016/j.ctrv.2018.10.007. Epub 2018 Oct 22.

Authors

Christoph Oing¹, Patrizia Giannatempo², Friedemann Honecker³, Karin Oechsle¹, Carsten Bokemeyer¹, Jörg Beyer⁴

Affiliations

¹ Department of Oncology, Hematology and Bone Marrow Transplantation with Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
³ ZeTuP Breast and Tumor Center, St. Gallen, Switzerland.
⁴ Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, CH-3031 Bern, Switzerland. Electronic address: joerg.beyer@insel.ch.

PMID: 30415106
DOI: 10.1016/j.ctrv.2018.10.007

Abstract

Most patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination chemotherapy. Yet, about 10-15% of metastatic GCC patients will eventually die of their disease. This narrative review focuses on treatment options when cure is no longer realistic.

Keywords: Drug therapy; Germ cell cancer; Germ cell tumor; Palliative treatment; Platinum-refractory.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Neoplasms / secondary
Bone Neoplasms / therapy
Brain Neoplasms / secondary
Brain Neoplasms / therapy
Humans
Immunotherapy / methods
Molecular Targeted Therapy / methods
Neoplasms, Germ Cell and Embryonal / pathology
Neoplasms, Germ Cell and Embryonal / therapy*
Palliative Care / methods*
Peripheral Nervous System Diseases / etiology
Psychosocial Support Systems

Substances

Antineoplastic Agents